Economy
M&A·IB
[Market In] Forced Sale of OGQ Founder’s Stake... Is It a Takeover or an Investor’s Right?
As compulsory sale proceedings for the founder’s stake in OGQ, South Korea’s largest intellectual property (IP) content startup, are underway, the founder’s side and the investors’ side are locked in …
Business·Industry
SamsungElectronics Wins Daesang for Eighth Consecutive Year, Led by AI Home Appliances
SamsungElectronics has won the “Daesang” for the eighth consecutive year, led by its home appliances featuring AI-based energy-saving technology. A wide range of AI appliances—including air conditione…
Business·Industry
Morocco to Invest 76 Trillion to Expand Accommodation Capacity by 20% Ahead of the 2030 World Cup
Morocco, which will co-host the 2030 FIFA World Cup with Spain and Portugal, is embarking on a massive investment initiative to transform its national infrastructure. The country plans to increase hot…
Business·Industry
[Blue Ocean Veterinary Medical Devices] ① Jeong Byeong-gon, President of the Korea Veterinary Medicines Association: “Focus on ‘Animal-Specific’ Products Derived from Human Medicines”
As medical technology advances, the treatment of human diseases is rapidly evolving into the era of “personalized medicine” and “precision medicine.” This shift is now spreading to the field of veteri…
M&A·IB
[Exclusive] IlyangPharmaceutical Completes Liquidation of Owner’s Family-Owned Company ‘Daebang Planning’… Bringing Management Reform to a Close
IlyangPharmaceutical(007570)has finalized the liquidation process for Daebang Planning, a family-owned company of the controlling family. The company plans to completely eliminate risks associated wit…
Business·Industry
'Largest Domestic M&A Deal': Samsung Bio, With Peptide Business, Solidifies Its Position as the World's No. 1 CDMO
SAMSUNG BIOLOGICS(207940)has signed the largest merger and acquisition (M&A) deal in South Korea’s pharmaceutical and biotech industry to produce peptide drugs, which are well known as ingredients in …
Business·Industry
Kolon TissueGene, Inc. Fails to Demonstrate Statistical Efficacy in Topline Results from U.S. Phase 3 Clinical Trial of ‘TG-C’ for Knee Osteoarthritis
“TG-C,” a cell-gene therapy candidate for knee osteoarthritis developed by Kolon TissueGene, Inc.(950160)—better known as Inbosa—failed to meet the primary efficacy endpoint in the topline results of …
Business·Industry
‘Patent Bills’ Mount Amid Memory Boom… A New Variable in the AI Supply Chain
As the memory semiconductor market experiences a boom driven by expanding investment in artificial intelligence (AI) data centers, patent disputes are emerging as a new business risk. With sales at me…
Business·Industry
From AI Data Centers to Automobiles… The Battle for Dominance in the Memory Market
Following the rise of artificial intelligence (AI) data centers, the importance of memory semiconductors is growing in software-defined vehicles (SDVs), such as autonomous cars, prompting even automak…
Business·Industry
Huons Co., Ltd. Announces Official Launch of Botulinum Toxin ‘HuTox’ Following Approval in China
Huons Group has successfully concluded the launch event for its botulinum toxin product “HuTox,” targeting mainland China’s massive cosmetic surgery market of 1.4 billion people, and has officially se…